| Identification | More | [Name]
Dorzolamide | [CAS]
120279-96-1 | [Synonyms]
(2r,4r)-2-ethylamino-4-methyl-5,5-dioxo-5,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide
DORZOLAMIDE
DORZOLAMIDE(SUBJECTTOPATENTFREE)
4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)-
4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S-trans)-
4S,6S-Dorzolamide
(4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-7,
Dorzalamide hydrochloride
7-dioxide-4H-Thieno[2,3-b]thiopyran-2-sulfonamide/ Dorzolamide | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C10H16N2O4S3 | [MDL Number]
MFCD00865636 | [Molecular Weight]
324.44 | [MOL File]
120279-96-1.mol |
| Chemical Properties | Back Directory | [Boiling point ]
575.8±60.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: soluble5mg/mL (clear solution, warmed) | [form ]
powder | [pka]
pKa 6.35 (Uncertain);8.50 (Uncertain) | [color ]
white to beige | [Optical Rotation]
[α]/D -25 to -35°, c = 1 in methanol | [InChI]
1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 | [InChIKey]
IAVUPMFITXYVAF-XPUUQOCRSA-N | [SMILES]
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O | [CAS DataBase Reference]
120279-96-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
36/37/38 | [Safety Statements ]
26 | [WGK Germany ]
3 | [RTECS ]
XJ9095169 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Uses]
Carbonic anhydrase inhibitor. | [Uses]
Dorzolamide is an intermediate in synthesizing N-Acetyl Dorzolamide (A173640), a useful synthetic compound. | [Definition]
ChEBI: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration
. A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. | [Brand name]
Trusopt (Merck). | [Biological Activity]
Dorzolamide is a potent carbonic anhydrase II inhibitor with an IC50 value of 0.16 nM on human erythrocyte carbonic anhydrase II in vitro. It has been found to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension. | [in vivo]
Dorzolamide (3, 10, or 30 mg/kg/day, ip) synergized mitomycin C exhibits anti-tumor activity in EAC solid tumor models. Dorzolamide produces a dose-dependent decrease in the calculated ratio (relative value of 57.3±1, 25.5±1.8, and 24.3± 0.7 %, respectively)[3].
| Animal Model: | Female Swiss albino mice (EAC solid tumor)[3]. | | Dosage: | 3, 10, or 30 mg/kg/day (synergized mitomycin C). | | Administration: | IP, daily for 3 weeks. | | Result: | Upregulated TXNIP and p53 while downregulated bcl-2.
Effective in retarding the growth of EAC in mice.
|
|
|
|